FSD Pharma Announces Appointments of Dr. Raza Bokhari as Interim CEO and Co-Chairman, Anthony Durkacz as Co-Chairman and Zeeshan Saeed as President

C.HUGE, FSD Pharma, cannabis, pot

The Board of Directors of FSD Pharma Inc. (“FSD Pharma” or the “Company“)          (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce the appointment of Dr. Raza Bokhari as interim CEO and Co-Chairman of the Board of Directors, replacing Thomas Fairfull. read more

FSD Pharma announces issuance of cannabis license under Excise Act

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) announced today that the Company’s application for a cannabis license under the Excise Tax Act has been conditionally approved by the Canada Revenue Agency (the “CRA“) and is effective as of October 17, 2018. The issuance of a cannabis license by the CRA is a requirement to sell cannabis and is a prerequisite to obtaining a sales license under the Cannabis Act. read more

FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, aNASDAQ Traded Pharmaceutical Company Focusing on the Development ofCannabinoid-Based Treatments, to Create Medical Cannabis IndustryInnovator

C.HUGE, FSD Pharma, cannabis, pot

Transaction combines two highly complementary businesses; the significant production and distribution of medical and recreational products by FSD Pharma, and the premium and differentiated medical and pharmaceutical brands by Therapix Biosciences; read more

FSD Pharma Featured on CTV Toronto

C.HUGE, FSD Pharma, cannabis, pot

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) is pleased to provide shareholders and interested parties with a link to the CTV Toronto program segment featuring interviews with executives and employees at the Company’s facility in Cobourg. In the segment, CEO and President Thomas Fairfull, Director Anthony Durkacz, and EVP and Director Zeeshan Saeed discuss job creation and the Company. read more

FSD Pharma and SciCann Therapeutics to Attend the CannX International Medical Cannabis Convention in Tel Aviv Israel

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that its Head of Scientific Advisory Board, Dr. Zohar Koren, will attend the 3rd International Medical Cannabis Conference, (“CannX”) in Tel Aviv, Israel from October 14 to 16, 2018. read more

FSD Pharma Congratulates High Tide Inc. for Closing Oversubscribed Private Placement and Announces $2 Million Lead Order

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (CSE: HUGE) (OTCQB: FSDDF) (FRA: OK9) (“FSD Pharma” or the “Company“) would like to congratulate High Tide Inc. (“High Tide“) on closing the second tranche of its brokered private placement (the “Offering“), for gross proceeds of approximately $18.3 million. The Offering, which was initially a $10 million financing, was upsized by over 83% due to strong demand from over 135 participating investors. read more

FSD Pharma Begins Construction of Heritage Museum and Flagship Dispensary in Ontario

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma” or the “Company“) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that construction has commenced of its heritage museum and flagship dispensary at the former Kraft plant in Cobourg, Ontario, headquarters of its wholly-owned subsidiary FV Pharma Inc. (“FV Pharma”). Local politicians and media will be in attendance at the ribbon-cutting ceremony on October 9, 2018 at 11:30 EST in Cobourg at the Head office located at 520 William Street. Honoured invited guests include Cobourg Mayor Gil Brocanier who will be in attendance and the Hon. Kim Rudd, MP for Northumberland and Peterborough South who is expected to attend. All national media are welcome with media credentials. read more

FSD Pharma Added to Leading Cannabis ETF With Significant 1.9% Weighting

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD Pharma” or the “Company”) (CSE: HUGE) (OTCQB: FSDDF) (FRA: 0K9) is pleased to announce that Horizons ETFs Management (Canada) Inc. (“Horizons ETFs”) has added the Company to the Horizons Marijuana Life Sciences Index ETF (“HMMJ:TSX“) as part of the quarterly rebalance of the constituent holdings of HMMJ. The Company stock has a 1.9% weighting in HMMJ. According to Horizons ETFs, “As at September 5, 2018, HMMJ had reached over CAD $1 billion in assets under management – a rare achievement for the Canadian ETF marketplace”.1 read more

FSD Pharma signs collaboration and profit sharing agreement with Canntab for production and market of oral dose delivery platforms

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) (“FSD Pharma” or the “Company), which, through its wholly-owned subsidiary FV Pharma Inc., is a licensed producer pursuant to the Access to Cannabis for Medical Purposes Regulations, is pleased to announce that it has signed a definitive collaboration and profit sharing agreement (the “Agreement“) with Canntab Therapeutics Limited (CSE:PILL) (“Canntab“), a leader in the rapidly growing cannabis pill market, effective September 17, 2018. Under the terms of the Agreement, FSD Pharma will assist Canntab to obtain a license to process and sell cannabis products pursuant to the Cannabis Act (the “License“), and will provide Canntab with space at its facility (the “FSD Facility“), which is located just one hour east of Toronto in Cobourg, Ontario (the “Transaction“). read more

FSD Pharma joins Snipp’s Cannabis Marketing Resource Center

C.HUGE, FSD Pharma, cannabis, pot
Cision

FSD Pharma Inc. (“FSD” or the “Company”) (CSE: HUGE) (OTC: FSDDF) (FRA: 0K9) today announced that it has joined the Cannabis Marketing Resource Center (“CMRC”) provided by Snipp Interactive Inc. (“Snipp”) (OTCQB: SNIPF; TSX-V: SPN), a global provider of digital marketing promotions, rebates and loyalty solutions. FSD has now joined some of the largest licensed producers in Canada that currently use the CMRC and the technology solutions provided by Snipp.  read more